ribociclib (kisqali) in inoperable or metastatic breast cancer-Beware QT prolongation

首页> 外文期刊>Prescrire international >ribociclib (kisqali) in inoperable or metastatic breast cancer-Beware QT prolongation

【24h】

ribociclib (kisqali) in inoperable or metastatic breast cancer-Beware QT prolongation

机译：Ribociclib（kisqali）在无法操作或转移性乳腺癌癌症 - 要延长

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

When fulvestrant is chosen as hormonal therapy for postmenopausal women with locally advanced or metastatic breast cancer, ribociclib appears to have a less favourable harm-benefit balance than abemaciclib, due to the arrhythmias provoked by ribociclib. Adding ribociclib to hormonal therapy extended survival in premenopausal women in one clinical trial. However, adding ribociclib to tamoxifen (the standard hormonal therapy) should be avoided, due to the high incidence of QT prolongation associated with this combination (reported in 17% of patients). The addition of ribociclib to an aromatase inhibitor was also evaluated. But the harm-benefit balance of aromatase inhibitors in premenopausal patients is uncertain as of mid-2020, and the combination of ribociclib + fulvestrant has not been evaluated.

机译：当氟维司坦被选为绝经后局部晚期或转移性乳腺癌患者的激素治疗时，由于核糖昔布引起的心律失常，核糖昔布似乎比阿贝马西布具有更不利的利弊平衡。在一项临床试验中，在激素治疗中加入核糖昔布可延长绝经前妇女的生存期。然而，应避免在他莫昔芬（标准激素疗法）中添加核糖昔布，因为与这种组合相关的QT延长发生率很高（17%的患者报告）。还评估了向芳香化酶抑制剂中添加核糖昔布的情况。但截至2020年年中，芳香化酶抑制剂在绝经前患者中的利弊平衡尚不确定，核糖昔布+富维司坦的组合尚未评估。

著录项

来源
《Prescrire international》 |2020年第217期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Stem cells, immortality, and the evolution of metastatic properties in breast cancer: telomere maintenance mechanisms and metastatic evolution [J] . Nathaniel J. Robinson, Derek J. Taylor, William P. Schiemann 癌症转移与治疗（英文版） . 2019,第005期
2. Stem cells, immortality, and the evolution of metastatic properties in breast cancer: telomere maintenance mechanisms and metastatic evolution [J] . Nathaniel J.Robinson, Derek J.Taylor, William P.Schiemann 癌症转移与治疗：英文版 . 2019,第005期
3. Principles of Monitoring Metastatic Disease and Chemotherapy Regimens for Recurrent or Metastatic Breast Cancer [J] . 国际转化医学杂志（英文版） . 2013,第002期
4. QT-interval prolongation during the treatment with ribociclib and endocrine agents in patients with hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer: A real-world experience [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Qt间隔在激素受体阳性阳性患者中核酸和内分泌试剂治疗期间延长，人体表皮生长因子2阴性转移性乳腺癌：真实的世界经验
5. THE INCIDENCE OF QT INTERVAL PROLONGATION IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER TREATED WITH RIBOCICLIB COMBINED WITH ENDOCRINE THERAPY IN A REAL-WORLD SETTING [J] . Kurbacher Christian Martin, Kurbacher A. Tabea, Schott Alexander, The Breast : . 2019,第Suppla2期

机译：用核核苷酸治疗的激素受体阳性，HER2阴性转移性乳腺癌患者QT间隔延长的发病率与真实世界的环境中内分泌治疗
6. Ribociclib (Kisqali (R)) from Novartis shows almost 5 Years of Overall Survival in pre- and perimenopausal Patients with HR+/ HER2-metastatic Breast Cancer [J] . Oncology research and treatment. . 2021,第3期

机译：来自Novartis的Ribociclib（kisqali（r））显示出在患有HR + / HER2-转移性乳腺癌的前周刊患者的近5年的整体生存期
7. Optical imaging of metabolic adaptability in metastatic and non-metastatic breast cancer [C] . Lisa Rebello, Narasimhan Rajaram Conference on Diagnosis and Treatment of Diseases in the Breast and Reproductive System . 2018

机译：转移性和非转移性乳腺癌代谢适应性的光学成像
8. Novel statistical approaches to assessing the risk of QT prolongation and sample size calculations in 'thorough QT/QTc studies'. [D] . Anand, Suraj P. 2009

机译：评估“全面QT / QTc研究”中QT延长风险和样本量计算的新颖统计方法。
9. Trastuzumab in combination with carboplatin and docetaxel does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study [O] . Na Xu, Charles H. Redfern, Michael Gordon, -1

机译：曲妥珠单抗联合卡铂和多西他赛不能延长HER2阳性转移性或局部晚期不能手术的实体瘤患者的QT间隔：Ib期研究结果
10. RIbociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2– inoperable locally advanced or metastatic breast cancer: RIGHT choice study [O] . N. El Saghir, S. Malwinder, H. Azim, 2019

机译：Ribociclib Plus Goserelin具有激素治疗与医生选择化疗在前肢或周末患者的HR +，Her2-不可操作的局部晚期或转移性乳腺癌：正确的选择研究
11. Q-T-Interval in Relatie tot Totale, Cardiovasculaire en IschaemischeHartziektesterfte: Een Prospektieve Studie onder Amsterdamse Ambtenaren (QT-Interval Prolongation Predicts Cardiovascular Mortality in the General Population) [R] . Meppelink, P. 1990

机译：Q-T-Interval in Relatie tot Totale，Cardiovasculaire en IschaemischeHartziektesterfte：Een prospektieve studie onder amsterdamse ambtenaren（QT-Interval延长预测一般人群中的心血管死亡率）

ribociclib (kisqali) in inoperable or metastatic breast cancer-Beware QT prolongation

摘要

著录项

相似文献

相关主题

期刊订阅